| Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling AM Mc Laughlin, PA Milligan, C Yee, M Bergstrand CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1577-1590, 2023 | 3 | 2023 |
| Model informed drug development: collaboration through a common framework RJ Anziano, PA Milligan Clinical Pharmacology and Therapeutics 110 (5), 1165, 2021 | 6 | 2021 |
| Open systems pharmacology community—an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences J Lippert, R Burghaus, A Edginton, S Frechen, M Karlsson, A Kovar, ... CPT: pharmacometrics & systems pharmacology 8 (12), 878, 2019 | 75 | 2019 |
| Translating pharmacometrics to a pharmacoeconomic model of COPD JF Slejko, RJ Willke, J Ribbing, P Milligan Value in Health 19 (8), 1026-1032, 2016 | 13 | 2016 |
| Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline L Claret, J Zheng, F Mercier, P Chanu, Y Chen, B Rosbrook, P Yazdi, ... Cancer chemotherapy and pharmacology 78, 605-610, 2016 | 7 | 2016 |
| Good practices in model‐informed drug discovery and development: practice, application, and documentation EFPIA MID3 Workgroup, SF Marshall, R Burghaus, V Cosson, ... CPT: pharmacometrics & systems pharmacology 5 (3), 93-122, 2016 | 259 | 2016 |
| Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients L Claret, F Mercier, BE Houk, PA Milligan, R Bruno Cancer chemotherapy and pharmacology 76, 567-573, 2015 | 22 | 2015 |
| Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ... CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015 | 41 | 2015 |
| Predicting Reductions in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations from FEV1-A Model-Based Meta-Analysis of Literature Data from Controlled Randomized Clinical … J Ribbing, J Korell, F Cerasoli, PA Milligan, SW Martin, MO Karlsson Journal of Pharmacokinetics and Pharmacodynamics 42 (S1), S63-S63, 2015 | 3 | 2015 |
| Good practices in model informed drug discovery and development (MID3): practice, application, documentation and reporting P Milligan, R Burghaus, V Cosson, SY Cheung, M Chenel, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 41, S31-S32, 2014 | 1 | 2014 |
| A Model Relating Overall Survival to Tumor Growth Inhibition in Renal Cell Carcinoma F Mercier, B Houk, L Claret, P Milligan, R Bruno Annals of Oncology 25, iv159, 2014 | | 2014 |
| PKPD modeling of predictors for adverse effects and overall survival in sunitinib‐treated patients with GIST EK Hansson, G Ma, MA Amantea, J French, PA Milligan, LE Friberg, ... CPT: pharmacometrics & systems pharmacology 2 (12), 1-9, 2013 | 53 | 2013 |
| PKPD modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST EK Hansson, MA Amantea, P Westwood, PA Milligan, BE Houk, J French, ... CPT: pharmacometrics & systems pharmacology 2 (11), 1-9, 2013 | 68 | 2013 |
| Model‐based drug development: a rational approach to efficiently accelerate drug development PA Milligan, MJ Brown, B Marchant, SW Martin, PH Van Der Graaf, ... Clinical Pharmacology & Therapeutics 93 (6), 502-514, 2013 | 248 | 2013 |
| The role of modeling and simulation in development and registration of medicinal products: output from the EFPIA/EMA modeling and simulation workshop E Manolis, S Rohou, R Hemmings, T Salmonson, M Karlsson, PA Milligan CPT: pharmacometrics & systems pharmacology 2 (2), 1-4, 2013 | 70 | 2013 |
| ENHANCING EARLY CRITICAL, ILLNESS RECOVERY THROUGH THE USE OF A'USER CENTRED CRITICAL CARE DISCHARGE INFORMATION PACK' S Bench, P Griffiths, P Hopkins, T Day, P Milligan, L Yardley, K Heelas, ... Intensive Care Medicine 38, S231-S231, 2012 | 1 | 2012 |
| PKPD-modeling of Standard Uptake Value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib E Schindler, P Westwood, M Amantea, EK Hansson, PA Milligan, ... PAGE Meeting, 2012 | 2 | 2012 |
| PKPD Modeling of Predictors for Side Effects and Overall Survival in Sunitinb Treated Patients with Gastro Intestinal Stromal Tumor E Hansson, G Ma, M Amantea, J French, P Milligan, L Friberg, M Karlsson | 1 | 2012 |
| Pharmacokinetic-Pharmacodynamic Modeling of VEGF, sVEGFR-2,-3 and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST E Hansson, M Amantea, P Westwood, P Milligan, B Houk, J French, ... | | 2012 |
| Telephone follow‐up to improve glycaemic control in patients with type 2 diabetes: systematic review and meta‐analysis of controlled trials L Wu, A Forbes, P Griffiths, P Milligan, A While Diabetic Medicine 27 (11), 1217-1225, 2010 | 81 | 2010 |
